Entero Therapeutics, Inc. (ENTO) Stock

About Entero Therapeutics, Inc.

Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company formerly known as First Wave BioPharma, Inc. (and prior to September 2021, AzurRx BioPharma, Inc.), is dedicated to discovering and advancing localized, non-systemic treatments for various gastrointestinal conditions. Its development pipeline features several key therapeutic candidates: latiglutenase, an oral biotherapeutic formulated to break down gluten into non-immunogenic peptides for celiac disease patients; adrulipase, a recombinant lipase enzyme engineered to facilitate the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist aimed at addressing gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for individuals with inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Furthermore, the company is developing CypCel, a management tool designed to monitor the intestinal health of recovering celiac disease patients. Founded in 2014, the company's operations are based in Boca Raton, Florida.

Entero Therapeutics, Inc. is headquartered in US.

Entero Therapeutics, Inc. (ENTO) stock trades at $2.85 with a market capitalization of $13.58M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.82, reflecting a net loss over the last twelve months, price-to-book of 0.76, price-to-sales of 173.38. Over the past 52 weeks the stock has ranged between $0.97 and $5.84, and currently trades 51.2% below its 52-week high.

On profitability, Entero Therapeutics, Inc. generates a return on equity (ROE) of -18.69% (negative, reflecting a net loss), return on capital employed of -31.12%.

Official website: www.firstwavebio.com

Entero Therapeutics, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Entero Therapeutics, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit rose to $-7.0M.

On a trailing twelve-month basis to Mar '26, revenue is $0 and net profit $-8.0M.

Borrowings stand at $2.0M, cash on hand is $385,542, cash from operations was $-6.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -44.3% over five years, and was -28.0% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Entero Therapeutics, Inc. (ENTO) — frequently asked questions